aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
IPO Year: 2026
Exchange: NASDAQ
Website: atyrpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2026 | $33.00 | Buy | Goldman |
| 2/23/2026 | $18.00 | Outperform | Robert W. Baird |
| 2/23/2026 | $21.00 | Mkt Outperform | Citizens |
| 2/23/2026 | $20.00 | Overweight | Barclays |
| 2/23/2026 | $23.00 | Buy | Deutsche Bank |
| 2/23/2026 | $13.00 | Overweight | Analyst |
| 2/23/2026 | $15.00 | Buy | Citigroup |
| 2/23/2026 | Outperform | William Blair | |
| 2/23/2026 | $15.00 | Buy | BofA Securities |
| 7/5/2023 | Outperform → Perform | Oppenheimer |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - Ethos Technologies Inc. (0001788451) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
SCHEDULE 13G - Ethos Technologies Inc. (0001788451) (Subject)
144 - Ethos Technologies Inc. (0001788451) (Subject)
144 - Ethos Technologies Inc. (0001788451) (Subject)
144 - Ethos Technologies Inc. (0001788451) (Subject)
SCHEDULE 13G - Ethos Technologies Inc. (0001788451) (Subject)
10-Q - Ethos Technologies Inc. (0001788451) (Filer)
8-K - Ethos Technologies Inc. (0001788451) (Filer)
8-K - Ethos Technologies Inc. (0001788451) (Filer)
8-K - Ethos Technologies Inc. (0001788451) (Filer)
424B4 - Ethos Technologies Inc. (0001788451) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00
Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00
Citizens initiated coverage of Ethos Technologies with a rating of Mkt Outperform and set a new price target of $21.00
Barclays initiated coverage of Ethos Technologies with a rating of Overweight and set a new price target of $20.00
Deutsche Bank initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $23.00
Analyst initiated coverage of Ethos Technologies with a rating of Overweight and set a new price target of $13.00
Citigroup initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $15.00
William Blair initiated coverage of Ethos Technologies with a rating of Outperform
BofA Securities initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $15.00
Oppenheimer downgraded aTyr Pharma from Outperform to Perform
Fastest customizable press release news feed in the world
AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball icon and 3x world champion David Ortiz. In a new campaign, Ortiz will share his profoundly personal story to help raise awareness about why life insurance can be an essential part of every family's financial protection plan—and how Ethos makes getting that coverage simple, fast, and accessible. "I've lost people I love more than anything, and I've almost lost my own life," said David Ortiz. "When you go through something like that, you stop thinking about tomorrow and start thinking about th
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at the following investor conferences. Event Details: Bank of America Global Technology Conference on June 2, 2026 at 2:00 p.m. PT / 5:00 p.m. ETBaird 2026 Global Consumer, Technology & Services Conference on June 3, 2026 at 11:00 a.m. PT / 2:00 p.m. ETWilliam Blair 46th Annual Growth Stock Conference on June 4, 2026 at 7:20 a.m. PT / 10:20 a.m. ET A live webcast of the presentations will be available on Ethos's investor relations website at investor
Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the terms of the lock-up agreements entered into in connection with Ethos's initial public offering has been satisfied. As a result, 25% of the eligible securities held by eligible holders as of February 15, 2026 ("Eligible Securities") will be automatically released from the lock-up restrictions immediately prior to opening of trading on May 14, 2026 and may be sold into the public market. The lock-up restrictions will continue to apply to all remaining shares subject to lock-u
Q1 Revenue grew 104% year-over-year to $193 millionQ1 Direct Channel Revenue grew 136% year-over-year to $146 millionQ1 Third-Party Revenue grew 42% year-over-year to $47 million AUSTIN, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the first quarter ended March 31, 2026. "Q1 is our seasonally strongest quarter, and this was an exceptional one," said Peter Colis, CEO and Co-Founder of Ethos. "Our results reflect both the velocity of our growth and the discipline of our execution. We are committed to protecting families at scale, a
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the launch of its native ChatGPT app, becoming the first life insurance provider to build a dedicated experience directly inside the world's most-used AI assistant. The integration is now available via the ChatGPT app store. The move positions Ethos at the intersection of two of the fastest-growing consumer behaviors: AI-assisted decision-making and digital-first financial services. With ChatGPT now reaching 900 million weekly active users, Ethos is meeting consumers where they are alrea
AUSTIN, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, and Liberty Mutual Insurance, today announced they are working together to expand the reach of Liberty Mutual's direct-to-consumer life insurance offering. By combining Liberty Mutual's trusted consumer brand with Ethos' best-in-class underwriting engine and digital platform, the collaboration marks a significant step forward in making life insurance more accessible, affordable and effortless for American families. Liberty Mutual will leverage Ethos' technology platform and proprietary underwriting engine to deliver a seam
AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio
AUSTIN, Texas and FREDERICK, Md., March 24, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced an expansion of its relationship with Banner Life Insurance Company ("Banner Life"), a leading provider of term life insurance, to offer two new Ethos-branded whole life insurance products, Simplified Issue Whole Life and Guaranteed Issue Whole Life through Ethos' technology platform. The collaboration marks a deepening of the two companies' relationship and extends Ethos' suite of final expense solutions to even more families across the country. Ethos has built one of the most advanced technology plat
AUSTIN, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at The Citizens Technology Conference in San Francisco. Event Details: Date: Tuesday, March 3, 2026Time: 11 AM PT / 2 PM ETWebcast: A live audio webcast of the presentation will be available on the Ethos Investor Relations website at investors.ethos.com. The presentation will be archived on the company's investor relations website for 90 days following the event. About Ethos Ethos is a leading life insurance technology company on a mission to prote
Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul
Live Leadership Updates
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin
SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice President, Regulatory Affairs. Dr. Ashworth will serve as a member of the company's executive leadership team, overseeing regulatory affairs functions and strategies. "aTyr is pleased to welcome Dr. Ashworth, an industry veteran who brings more than 35 years of regulatory and drug development experience, including a proven track record of contributing to the FDA approval of more than 12 new drugs across a broad range o
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the company's Board of Directors. Dr. Zaknoen is an experienced pharmaceutical drug development and clinical research executive having previously served as Chief Medical Officer at several biotech companies. "We are very pleased to welcome Sara, a highly accomplished executive with experience in drug development, to our Board of Directors," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "While we
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Andrea Wilson as a patient advisor to the company. Ms. Wilson, a sarcoidosis patient and advocate, co-founded the Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients, and previously served as President and a member of its Board of Directors, including Chairwoman. “We are pleased during Sarcoidosis Awareness Month to welcome
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to the company. Dr. Varner currently serves as Professor in the Departments of Pathology and Medicine at the Moores Cancer Center at the University of California, San Diego (UCSD). “We are pleased to announce Dr. Varner as a scientific advisor to our company and welcome the opportunity to work with an expert that is local to San Diego and has a world-renowned reputation in the area of cancer biology,” said
Live finance-specific insights
AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio
Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value driver efzofitimod program. Ended the third quarter 2022 with $79.6 million in cash, restricted cash, cash equivalents and investments. Company to host conference call and webcast today, November 10th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quart
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, November 10, 2022Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI4b50025644f64e129d555aeb8993aeb1Webca
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments. Company to host conference call and webcast today, May 15th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update. "We are
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter 2022 financial results and provide a corporate update after the market close on Monday, August 15, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Monday, August 15, 2022Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI5d7604e9c0b54bbc88aaa9841cb67823Webcast Regi
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD. Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, May 9th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NA
This live feed shows all institutional transactions in real time.
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G - aTYR PHARMA INC (0001339970) (Subject)
SC 13G - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)